Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.83 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.83 |
| ▸ | TSHR | P16473 | 5/20 | 0.83 |
| ▸ | SLC9A5 | Q14940 | 5/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | GLA | P06280 | 3/20 | 0.83 |
| ▸ | HPGD | P15428 | 3/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.83 |
| ▸ | GAA | P10253 | 2/20 | 0.83 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.83 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.83 |
| ▸ | BLM | P54132 | 2/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL27563 | 0.91 | PLAU (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL29531132 | 0.91 | PLAU (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL4155066 | 0.89 | ALDH1A1 (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL136682 | 0.87 | PLAU (0.93) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL871514 | 0.86 | PLAU (0.90) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL10087514 | 0.86 | PLAU (0.73) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL20819986 | 0.85 | PLAU (0.66) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL9852481 | 0.82 | CYP1A2 (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL15290919 | 0.82 | PLAU (0.67) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL29406659 | 0.82 | CYP1A2 (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546322-B2 | Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546322-B2 | Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546322-B2 | Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120108494-A1 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108494-A1 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108494-A1 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2185153-A2 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009020877-A2 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| US-4604394-A | Antiarrhythmic compositions and method | MERCK & CO., INC. (US) | 1986-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108494-A1 | INHIBITORS OF INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR AND METHODS OF USE THEREOF | PLAU, PLAUR, DNPEP | PLAU 1/4885CYP1A2 4875/4885SLC9A1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.